BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

Introduction of the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021

General 1 min
March 2, 2021

On the 3rd February 2021, the Narcotic Drugs Amendment (Medicinal Cannabis) Bill 2021 (Bill) was introduced into the Australian Parliament. The Bill aims to streamline the current regulatory scheme for cultivation, production, research and manufacture of medicinal cannabis.

The Bill encompasses amendments to the Narcotic Drugs Act 1967 (Act) to reflect recommendations that came out of a review of the Act. The objectives of the Act are to prevent abuse and diversion of controlled narcotics and to ensure the availability of such drugs for medical and research purposes, pursuant to the Single Convention on Narcotic Drugs. From October 2016, the Act was extended to regulate of cannabis cultivation and production in Australia and to facilitate the supply of medicinal cannabis products for therapeutic purposes.

Key aspects of the Bill include provisions to:

  • reduce the burden of the licence assessment process, by providing for a single medicinal cannabis licence to replace the suite of licences currently required for cultivation, production, manufacture and research activities; and
  • provide for the majority of licences to be permanent.

We will provide further updates on the passage of this Bill through the Australian Parliament as they occur.

Written by
Shehana Wijesana
Shehana Wijesana
As Counsel in our Intellectual Property Group in Sydney, I advise our clients on all aspects of IP strategies, protection, exploitation and enforcement. I enjoy assisting clients with developing, protecting and enforcing their valuable IP rights. The key sectors of interest for me are life sciences, education and retail and consumer industries. All three present an abundance of differing IP issues from development, to commercialisation to enforcement. I find true satisfaction in helping clients reach commercial conclusions to their IP disputes and to me this is one of the key service offerings we can provide our clients.

Related articles

More Guidance on Pharma Settlement Agreements from the Court of Justice of the EU (ECJ)
It is clear that under certain specific circumstances, a settlement agreement between a holder of a pharmaceutical...
Telemedicine in France: state of play
Telemedicine is governed by Article L6316-1 and R6316-1 and seq of the French public health code...
Illumina v MGI: Patents Court gives guidance on the skilled person, CGK, and insufficiency
In Illumina v Latvia MGI Tech (MGI) [2021] EWHC 57 (Pat), Birss J (as he...
Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.